

REMARKS

Claims 3 and 8 have been amended to address certain informalities and new claims 21 and 22 are submitted herewith to claim the preferred subject matter of those claims. No new matter is submitted herewith.

The Examiner required restriction between the following which was defined as follows:

"This application contains claims directed to more than one species of the generic invention. ... Each combination of one disclosed secretory cleavage sequence and one protein having secretase activity represents a species."

Applicants hereby elect as their secretory cleavage sequence, the beta-site of APP and the β -secretase of human APP as their protein having secretase activity.


Claims 1-20 and new claims 21 and 22 are readable upon the elected species.

CONCLUSION

Should the Examiner have any further comments or suggestions regarding the above-identified application, he is encouraged to contact the undersigned attorney at the number below.

Dated: December 4, 2007

Respectfully submitted,

By 
Jeffrey S. Sharp

Registration No.: 31,879
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant